In reply [5]

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3857-3858

  Peng, Bin ^a   Capdeville, Renaud ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ACROLEIN; CGP 74588; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUCONAZOLE; IMATINIB; ITRACONAZOLE; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LETTER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 33846965957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.308     Document Type: Letter

References (14)

1. Peng B, Hayes M, Resta D, et al: Clinical investigation of the pharmacokinetics and pharmacodynamics of imatinib in a phase 1 trial in chronic myeloid leukemia patients. J Clin Oncol 22:935-942, 2004
2. Nikolova Z, Peng B, Hubert M, et al: Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 53:433-438, 2004
3. Bolton AE, Peng B, Hubert M, et al: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Glivec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106, 2004
4. Dutreix C, Peng B, Mehring G, et al: Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294, 2004
5. O'Brien SG, Meinhardt P, Bond E, et al: Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89:1855-1859, 2003
6. Prueksaritanont T, Gorham LM, Ma B, et al: In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199, 1997
7. Marr KA, Leisenring W, Grippa F, et al: Cyclophosphamide metabolism is affected by azole antifungals. Blood 103:1557-1559, 2004
8. Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396-4407, 2004
9. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. Blood 104:3507-3512, 2004
10. Wassmann B, Pfeifer H, Scheuring U, et al: Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 16:2358-2365, 2002
11. Deininger MWN, Schleuning M, Olavarria E, et al: Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience. Bone Marrow Transplant 29:31, 2002 (suppl 2; abstr 185)
12. Shimoni A, Kroger N, Rowe JM, et al: Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia positive acute leukemia. Leukemia 17:290-297, 2003
13. Wabersich M, Krahl R, Lange T, et al: Imatinib in the pre- and post-transplantation setting in Philadelphia chromosome positive CML: A retrospective analysis. Bone Marrow Transplant 33:S149-S150, 2004 (suppl 1; abstr 615)
14. Koch M, Lang P, Bader P, et al: Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year old male. Bone Marrow Transplant 32:541-542, 2003